Warfarin therapy: evolving strategies in anticoagulation
- PMID: 10029789
Warfarin therapy: evolving strategies in anticoagulation
Erratum in
- Am Fam Physician 1999 Oct 1;60(5):1333
- Am Fam Physician 2002 Jan 15;65(2):172
- Am Fam Physician. 2006 Mar 15;73(6):974
Abstract
Warfarin is the oral anticoagulant most frequently used to control and prevent thromboembolic disorders. Prescribing the dose that both avoids hemorrhagic complications and achieves sufficient suppression of thrombosis requires a thorough understanding of the drug's unique pharmacology. Warfarin has a complex dose-response relationship that makes safe and effective use a challenge. For most indications, the dose is adjusted to maintain the patient's International Normalized Ratio (INR) at 2 to 3. Because of the delay in factor II (prothrombin) suppression, heparin is administered concurrently for four to five days to prevent thrombus propagation. Loading doses of warfarin are not warranted and may result in bleeding complications. Interactions with other drugs must be considered, and therapy in elderly patients requires careful management. Current dosing recommendations are reviewed, and practical guidelines for the optimal use of warfarin are provided.
Comment in
-
Monitoring warfarin therapy.Am Fam Physician. 1999 Sep 1;60(3):764, 766. Am Fam Physician. 1999. PMID: 10498107 No abstract available.
Similar articles
-
[Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].Acta Chir Orthop Traumatol Cech. 2004;71(4):237-44. Acta Chir Orthop Traumatol Cech. 2004. PMID: 15456102 Czech.
-
Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.Am J Med. 2005 Feb;118(2):137-42. doi: 10.1016/j.amjmed.2004.07.053. Am J Med. 2005. PMID: 15694897 Clinical Trial.
-
Patient factors that influence warfarin dose response.J Pharm Pract. 2010 Jun;23(3):194-204. doi: 10.1177/0897190010362177. Epub 2010 May 6. J Pharm Pract. 2010. PMID: 21507814 Review.
-
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004 Sep;126(3 Suppl):204S-233S. doi: 10.1378/chest.126.3_suppl.204S. Chest. 2004. PMID: 15383473
-
[Hemorrhagic complications during warfarin treatment].Vnitr Lek. 2006 Mar;52 Suppl 1:79-91. Vnitr Lek. 2006. PMID: 16637455 Review. Czech.
Cited by
-
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.Br J Clin Pharmacol. 2013 Nov;76(5):776-86. doi: 10.1111/bcp.12106. Br J Clin Pharmacol. 2013. PMID: 23451769 Free PMC article. Clinical Trial.
-
Preemptive Dose Adjustment Effect on the Quality of Anticoagulation Management in Warfarin Patients With Drug Interactions: A Retrospective Cohort Study.Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619872554. doi: 10.1177/1076029619872554. Clin Appl Thromb Hemost. 2019. PMID: 31482725 Free PMC article.
-
A survey of pediatric cardiology nurses' understanding of warfarin therapy.Pediatr Cardiol. 2006 Mar-Apr;27(2):204-8. doi: 10.1007/s00246-005-1087-0. Pediatr Cardiol. 2006. PMID: 16261273
-
Evaluation of a protocol for early detection of delayed brain hemorrhage in head injured patients on warfarin.Eur J Trauma Emerg Surg. 2019 Jun;45(3):481-487. doi: 10.1007/s00068-018-0924-9. Epub 2018 Mar 14. Eur J Trauma Emerg Surg. 2019. PMID: 29541804
-
Updates on the clinical evidenced herb-warfarin interactions.Evid Based Complement Alternat Med. 2014;2014:957362. doi: 10.1155/2014/957362. Epub 2014 Mar 18. Evid Based Complement Alternat Med. 2014. PMID: 24790635 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical